FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 294:507-511 March 4, 1976 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

DDAVP, 1-desamino-8-d-arginine-vasopressin, is a synthetic analogue of vasopressin with increased antidiuretic activity and decreased pressor activity. Whereas the antidiuretic-to-pressor ratio of arginine vasopressin is 1, the antidiuretic-to-pressor ratio of DDAVP is 4000. When administered as an intranasal spray, 5 to 20 mug of DDAVP produced eight to 20 hours of antidiuresis in patients with complete central diabetes insipidus. The minimum recommended therapeutic dose resulted in a maximum antidiuresis in most patients. No side effects of the drug were noted in clinical trials. DDAVP thus gives promise of becoming the standard treatment of severe central diabetes insipidus.

This article has been cited by other articles:

• Pesaturo, A. B, Jennings, H. R, Voils, S. A (2006). Terlipressin: Vasopressin Analog and Novel Drug for Septic Shock. The Annals of Pharmacotherapy 40: 2170-2177 [Abstract] [Full Text]  
• Osterberg, O., Savic, R. M., Karlsson, M. O., Simonsson, U. S. H., Norgaard, J. P., Walle, J. V., Agerso, H. (2006). Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults.. J Clin Pharmacol 46: 1204-1211 [Abstract] [Full Text]  
• Neveus, T., Lackgren, G., Tuvemo, T., Stenberg, A. (1999). Osmoregulation and Desmopressin Pharmacokinetics in Enuretic Children. Pediatrics 103: 65-70 [Abstract] [Full Text]  
• HjalmAs, K., Bengtsson, B. (1993). Efficacy, Safety, and Dosing of Desmopressin For Nocturnal Enuresis in Europe. CLIN PEDIATR 32: 19-24 [Abstract]